tirzepatide cardiovascular outcomes trial results august 2025 US Population Eligibility and Estimated Impact of Treatment on Obesity Prevalence and Disease Events | Cardiovascular Drugs and Therapy Tirzepatide cardiovascular event risk assessment:

M., Triguero, D., Buciak, J

A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice The study examines the effectiveness of novel peptides that are a combination of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon

Fibers help slow down digestion

CARMELINA investigators

For retatrutide specifically, the beyond-use date (BUD) that is, the date after which the reconstituted solution must be discarded must be determined by the sponsor's validated stability data as documented in the IMPD or manufacturer's specification

Additionally, combining L-Carnitine with branched-chain amino acids (BCAAs) can support muscle recovery and growth